Anthropic announced at The Briefing: AI for Science event that it intends to develop its own drugs using Claude Science, a new workbench designed to consolidate fragmented scientific tools and datasets. The company claims this platform will generate figures and visualisations while pulling together information previously scattered across different systems. Anthropic stated the goal is to accelerate scientific discovery and healthcare intervention development, noting that several biotech and pharmaceutical customers already utilise the technology for their research workflows.
This move represents a significant shift for an AI firm known primarily for coding assistants and chat interfaces. By entering drug development directly, Anthropic risks high capital expenditure and regulatory hurdles unlike its software business. The strategy aims to prove that generative models can handle complex biological data to create tangible medical solutions rather than just generating text.
* Anthropic plans to build internal drug candidates alongside external client work
* The new tool integrates data sources that scientists usually manage separately
* Regulatory approval remains a critical barrier for any AI-generated medicine
